Biostatistics, Epidemiology & Environmental Health Sciences: Faculty Publications
Statistical Considerations for Clinical Trials During COVID-19: Background
Document Type
Article
Publication Date
3-29-2020
Publication Title
Abstract
The emergence of COVID-19 in a few weeks has posted various unprecedented challenges world-wide, including overwhelming stress on health care infrastructures of different countries. This also substantially affects current ongoing or near future clinical trials for drug development for various diseases, including cancer and other serious diseases, particularly where patients are immunocompromised. In response, the U.S. Food and Drug Administration (FDA) issued the guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. To mitigate challenges in conducting clinical trials during COVID-19, the FDA recognizes that protocol modifications may be required. Specifically, the guidance states...
Recommended Citation
Liu, Qing, Karl E. Peace.
2020.
"Statistical Considerations for Clinical Trials During COVID-19: Background."
LinkedIn.
source: Linkedin.com
https://digitalcommons.georgiasouthern.edu/bee-facpubs/141
Copyright
This work is archived and distributed under the repository's Standard Copyright and Reuse License (opens in new tab). End users may copy, store, and distribute this work without restriction. For all other uses, permission must be obtained from the copyright owners or their authorized agents.
